In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan

Katsunori Yanagihara, Kazuhiro Tateda, Yohei Doi, Satoshi Takahashi, Hiroki Ohge, Koju Itahashi, Hayato Okade, Hiroshige Mikamo · 2026

Read In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan by Katsunori Yanagihara, Kazuhiro Tateda, Yohei Doi, Satoshi Takahashi, Hiroki Ohge, Koju Itahashi, Hayato Okade, Hiroshige Mikamo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13231151.txt.

Description

Katsunori Yanagihara and team test in 2026 a new drug that helps two older drugs beat tough gut germs. The new drug, nacubactam, blocks enzymes that germs use to break down last-line drugs. Labs checked close to four hundred tough strains from six sites in Japan.

About half the strains made those enzymes, led by types most seen in Japan. Pairs of nacubactam with cefepime or with aztreonam stopped growth at low doses in most strains. The pairs beat two older paired drugs on key lab tests in this set. Such strong lab results back the pairs as future options for hard infections, while trials in patients move ahead in Japan.

Catalog record

CREATORKatsunori Yanagihara, Kazuhiro Tateda, Yohei Doi, Satoshi Takahashi, Hiroki Ohge, Koju Itahashi, Hayato Okade, Hiroshige Mikamo
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13231151

Browse the full library · About the Tower of Babel